Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:22 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment
NCT02523768 · Centre Hospitalier Universitaire de Saint Etienne · PHASE4 · terminated · last registry update 2021-01-20 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Difficulties for recruting patients” | – | Registry record, Centre Hospitalier Universitaire de Saint Etienne |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL2RA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-01-05Results posted on the registry: Astellas Pharma Global Development, Inc., Bleselumab + Basiliximab (NCT02921789)
- 2021-12-15Also stopped (terminated): National Cancer Institute (NCI), E7 T-Cell Receptor (TCR) (NCT04476251)
- 2021-12-08Results posted on the registry: National Cancer Institute (NCI), E7 T-Cell Receptor (TCR) (NCT04476251)
- 2021-10-29Also stopped (terminated): Fred Hutchinson Cancer Center, Aldesleukin + Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes (NCT02770820)
- 2021-10-25Results posted on the registry: University of Louisville, Ipilimumab (NCT02009384)
- 2021-10-25Also stopped (terminated): University of Louisville, Ipilimumab (NCT02009384)
- 2021-09-13Results posted on the registry: Fred Hutchinson Cancer Center, Aldesleukin + Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes (NCT02408016)
- 2021-09-13Also stopped (terminated): Fred Hutchinson Cancer Center, Aldesleukin + Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes (NCT02408016)
- 2021-08-23Results posted on the registry: University of Texas Southwestern Medical Center, IL-2 (NCT01896271)
- 2021-08-04Results posted on the registry: Jonsson Comprehensive Cancer Center, F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells + non-myeloablative conditioning chemotherapy (NCT00910650)
- 2021-07-13Results posted on the registry: ADC Therapeutics S.A., Camidanlumab tesirine (NCT02432235)
- 2021-06-24Results posted on the registry: Anil K. Chandraker, MD, aldesleukin (NCT02417870)
- 2021-06-24Also stopped (terminated): Anil K. Chandraker, MD, aldesleukin (NCT02417870)
- 2021-06-23Results posted on the registry: Fred Hutchinson Cancer Center, Aldesleukin + Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes (NCT02770820)
- 2021-06-08Results posted on the registry: Novartis Pharmaceuticals, Aldesleukin (NCT00414765)
- 2021-05-20Phase 3 first posted: Second Xiangya Hospital of Central South University, Recombinant human interleukin-2 (rhIL-2) + Control group (NCT04893980)
- 2021-04-06Results posted on the registry: CellTrans Inc., Islets of Langerhans transplantation (NCT00679042)
- 2021-03-24Results posted on the registry: National Cancer Institute (NCI), Anti-NY ESO-1 mTCR PBL + Cyclophosphamide (NCT01967823)
- 2021-02-24Results posted on the registry: National Cancer Institute (NCI), Aldesleukin + Entinostat (NCT01038778)
- 2021-02-16Also stopped (terminated): National Cancer Institute (NCI), Aldesleukin + E6 T Cell Receptor (TCR) (NCT03197025)
- 2021-02-04Phase 3 first posted: Peking University People's Hospital, UC-MSC + Anti-CD25 mAb (NCT04738981)
- 2021-02-01Also stopped (withdrawn): National Cancer Institute (NCI), Cyclophosphamide + Fludarabine (NCT04536922)
- 2021-02-01Also stopped (terminated): Clinigen, Inc., vemurafenib + HD IL-2 (NCT01683188)
- 2021-01-26Phase 3 first posted: University of Sao Paulo, Ixekizumab + Aldesleukin (NCT04724629)
- 2021-01-26Also stopped (terminated): University of Chicago, 4-peptide melanoma vaccine + Ontak (NCT00515528)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision